Next Article in Journal
Molecular Targets and Novel Therapeutic Avenues in Soft-Tissue Sarcoma
Previous Article in Journal
Immunotherapy in Soft-Tissue Sarcoma
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma

BC Cancer–Vancouver Centre, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s1), 25-33; https://doi.org/10.3747/co.27.5475
Received: 8 November 2019 / Revised: 5 December 2019 / Accepted: 11 January 2020 / Published: 1 February 2020
Background: Soft-tissue sarcoma (sts) represents a rare group of mesenchymal neoplasms comprising more than 50 heterogeneous subtypes. Great efforts have been made to increase the understanding of the treatment of advanced sts (unresectable or metastatic disease). We set out to determine whether outcomes for patients with advanced sts have improved over time and to assess the current evidence for systemic therapy. Methods: In a scoping review, we evaluated the contemporary evidence for systemic treatment of advanced sts in adults (>18 years of age). Phase i, ii, and iii studies of systemic therapy for advanced sts published in the English language were included. After abstract and full-text review of seventy-seven studies, sixty-two trials met the inclusion criteria. Results: The number of clinical trials conducted and published in advanced sts has increased over the last 30 years. Although median overall survival has increased, attempts at improving first-line therapy through dose intensification, doublet chemotherapy, or alternative backbones have not been successful. The optimal therapy beyond anthracyclines remains a challenge, especially given the heterogeneity that grouping multiple sts subtypes within clinical trials creates. However, increasing numbers of agents are being studied, and several studies had shown isolated benefit in progression-free or overall survival. Summary: First-line systemic therapy with an anthracycline remains the standard of care for advanced sts. However, choice of subsequent therapy beyond anthracyclines remains challenging. Novel systemic therapies, use of molecular diagnostics to direct therapy, subtype-specific trials, and learnings from real-world retrospective data are all important for improving outcomes in patients with advanced sts.
Keywords: soft-tissue sarcoma; advanced; systemic therapy; anthracyclines soft-tissue sarcoma; advanced; systemic therapy; anthracyclines
MDPI and ACS Style

Smrke, A.; Wang, Y.; Simmons, C. Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma. Curr. Oncol. 2020, 27, 25-33. https://doi.org/10.3747/co.27.5475

AMA Style

Smrke A, Wang Y, Simmons C. Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma. Current Oncology. 2020; 27(s1):25-33. https://doi.org/10.3747/co.27.5475

Chicago/Turabian Style

Smrke, A., Y. Wang, and C. Simmons. 2020. "Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma" Current Oncology 27, no. s1: 25-33. https://doi.org/10.3747/co.27.5475

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop